| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-11-0483 |
| P698 | PubMed publication ID | 22003068 |
| P50 | author | Dario Neri | Q42611693 |
| P2093 | author name string | Martina Steiner | |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 6406-6416 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends | |
| P478 | volume | 17 |
| Q42333450 | 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. |
| Q35192223 | A highly functional synthetic phage display library containing over 40 billion human antibody clones |
| Q28487973 | A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma |
| Q37593714 | A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer |
| Q63406959 | A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing |
| Q30620931 | Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. |
| Q35446035 | Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox |
| Q39100229 | Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia |
| Q37994278 | Antibody-based immunotherapy of cancer |
| Q36551498 | Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation |
| Q38364462 | Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs |
| Q38151738 | Cancer immunotherapy: accomplishments to date and future promise |
| Q92585782 | Considerations for the Design of Antibody-Based Therapeutics |
| Q38017203 | Designing immunoconjugates for cancer therapy |
| Q38920025 | Development of a high affinity, non-covalent biologic to add functionality to Fabs |
| Q37559740 | Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12. |
| Q42365479 | EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer |
| Q38741288 | Engineering a targeted delivery platform using Centyrins |
| Q36915057 | Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy |
| Q39185087 | Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications |
| Q84140031 | Hepatic artery injection of ¹³¹I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study |
| Q38042256 | Immunoconjugates and long circulating systems: origins, current state of the art and future directions |
| Q91973876 | In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predicts Partitioning and Pharmacokinetics |
| Q36018529 | MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. |
| Q47367962 | Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events |
| Q36881360 | Methodology for labeling proteins and peptides with lead-212 (212Pb) |
| Q35662815 | Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab |
| Q38388962 | Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. |
| Q49539698 | Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
| Q39189330 | Nanoparticles exposing neurotensin tumor-specific drivers. |
| Q38249954 | Overcoming multidrug resistance with nanomedicines |
| Q35870549 | Pharmacodynamic study of (131)I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer |
| Q38022192 | Pharmacokinetic considerations for antibody drug conjugates |
| Q51749302 | Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay. |
| Q91745562 | Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma |
| Q39273739 | Protein based therapeutic delivery agents: Contemporary developments and challenges |
| Q55074250 | Recent developments in multimodality fluorescence imaging probes. |
| Q36429037 | SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies |
| Q35992503 | Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein |
| Q37593705 | Site-specific antibody drug conjugates for cancer therapy |
| Q26780335 | Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics |
| Q36752488 | Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb |
| Q36217155 | Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity |
| Q28550176 | Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine |
| Q26801364 | Targeted radionuclide therapies for pancreatic cancer |
| Q38662743 | Targeted radionuclide therapy in combined-modality regimens. |
| Q39001331 | Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts |
| Q34402770 | Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors |
| Q50100063 | The NISTmAb tryptic peptide spectral library for monoclonal antibody characterization |
| Q27021990 | The development of immunoconjugates for targeted cancer therapy |
| Q90294900 | Thera-SAbDab: the Therapeutic Structural Antibody Database |
| Q38261959 | Vectors for the delivery of radiopharmaceuticals in cancer therapeutics |
Search more.